News Archive

2025

Cerebrolysin® as an Adjunct Therapy to Mechanical Thrombectomy - 26.06.2025AMN CONGRESS IN BANGKOK, THAILAND - 06.06.2025Is there sufficient evidence to include Cerebrolysin® into treatment algorithms in AIS? - 20.05.2025ESOC 2025 - Visit the EVER Pharma Symposium - 22.04.2025Interview with 2 Aphasia Experts - 15.04.2025Cerebrolysin® as an Adjuvant Therapy After Mechanical Thrombectomy in Cardioembolic Stroke - 03.04.2025Today is “Brain Injury Awareness Day” – Let’s talk about Brain Trauma and Depression - 20.03.2025ESCAS confirms efficacy of Cerebrolysin® in aphasia patients - 05.03.2025Join the webinar - Is there sufficient evidence to include Cerebrolysin® into treatment algorithms in AIS? - 19.02.2025Traumatic Brain Injury – Understanding Diffuse Axonal Injury and its impact - 06.02.2025Opening the Vessel Is Not Enough – Is Cerebrolysin® the Answer for Improved Long-Term Outcomes After Recanalization Therapy? - 21.01.2025WSC 2024, Abu Dhabi - EVER Symposium - 07.01.2025

2024

Join the webinar - Opening the vessel is not enough! - 18.10.2024WSC 2024 - Visit us! - 24.09.2024ESOC 2024, Basel - EVER Symposium - 30.08.2024New guideline inclusion for Cerebrolysin® in stroke - 23.08.2024NTSC & AMN change treatment paradigms in neurotrauma - 30.07.2024EVER Pharma joins forces with EFNR & ESO to revolutionize Post-Stroke Rehabilitation Training - 15.07.2024A review recognizing Cerebrolysin® as a cytoprotective and neurogenerative drug treating secondary damage after sTBI - 01.07.2024Review about EVER webinar 'Cerebroylsin's evidence from TBI research' - 18.06.2024ESOC 2024 - New study in aphasia presented - 11.06.2024AMN CONGRESS IN VIENNA, AUSTRIA - 07.05.2024Cerebrolysin® – the sole pharmacological agent supported by evidence for brain trauma recovery! - 30.04.2024Training programs for neurorehabilitation after stroke – A new era begins! - 15.04.2024ESOC 2024 - Visit the EVER Pharma Symposium - 02.04.2024World Head Injury Awareness Day - 20.03.2024Join the webinar - Cerebrolysin's evidence from TBI research - 08.03.2024Multidisciplinary Neurotrauma Treatment - Panel discussion - 29.02.2024BIG MILESTONE - Global guideline recommendations - 16.02.2024ESICM 2023 - EVER Symposium - 31.01.2024Cost-Effectiveness of Cerebrolysin® - 17.01.2024

2023

Highlights of the IMMM 2023 - 12.12.2023New video about effects of Cerebrolysin® in TBI patients - 17.11.2023First comprehensive Cerebrolysin® treatment handbook - 08.11.2023World Stroke Day 2023 - 29.10.2023New Webinar: Multidisciplinary Neurotrauma treatment - Panel discussion - 11.10.2023ESICM 2023 - Visit the EVER Pharma Symposium - 27.09.2023Review about EVER Webinar 'Treatment strategies for motor impaired stroke patients' - 16.08.2023New positive trial in acute stroke published - 21.07.2023ESOC 2023, Munich - EVER Symposium - 06.07.2023NIBS - TRIPLE-Therapy Workshop - 15.06.2023The 2. NTSC Vienna – A successful continuation - 01.06.2023New Webinar: Treatment strategies for motor impaired stroke patients - 15.05.2023First inclusion of Cerebrolysin® in TBI guideline! - 09.05.2023ESOC 2023 - Visit the EVER Pharma Symposium - 03.05.2023Cerebroprotective strategies in acute ischemich stroke – fiction or reality? - 18.04.2023STAIR XII meeting in Washington DC - 06.04.2023Cerebrolysin® reduces hospital stay in TBI patients - 20.03.202320th AMN Congress - 03.03.2023New Webinar: Cerebroprotective strategies in acute ischemic stroke - fiction or reality? - 17.02.2023Case reports - 2 patients benefit from a new multi-modal pharmacological treatment concept - 07.02.2023Review about EVER Webinar ‘The future of chronic stroke patient treatment‘ - 31.01.2023Experts talk about treatments after stroke - 10.01.2023

2022

Watch the new video about cognitive impairment - 21.12.2022Review about EVER Webinar 'Neurorecovery - When evidence from the bench meets results at the bedside' - 13.12.2022Multidisciplinary Treatment Concept in Brain Trauma - An Unique Program - 01.12.2022Expert Interview Prof. Maas - 15.11.2022The future of chronic stroke patient treatment – Interactive case discussion - 02.11.2022World Stroke Day, October 29th - 28.10.2022Review about EVER Webinar ‘Treating cognitive decline after critical illnesses’ - 21.10.2022Neurorecovery – When evidence from the bench meets results at the bedside - 14.09.2022CERECAP Update - 02.09.2022A Call to Action – Treating cognitive decline after critical illnesses - 12.08.2022Review Case Discussions 'New horizons improving gold standard therapy in acute stroke' - 21.07.2022Cognitive Impairment? Cerebrolysin® helps! - 14.07.2022Review about webinar 'Get with the guidelines in post-stroke motor recovery' - 01.07.2022Review about EVER Webinar 'Evidence-based neurorecovery after stroke and TBI' - 03.06.2022New Webinar: New horizons improving gold standard therapy in acute stroke - 25.05.2022ECOMPASS Meta-Analysis about efficacy of Cerebrolysin® in stroke - 02.05.2022Join the Expert panel discussion: Get with the guidelines - 22.04.2022Neurotrauma Treatment Simulation Center (NTSC) - 06.04.2022Post stroke rehabilitation exchange programs - 16.03.2022New Webinar: Evidence-based neurorecovery after stroke and TBI - 02.03.2022Webinar report - The renaissance of neuroprotection in times of recanalization therapies - 31.01.2022Illustrated book about the events after an ischemic stroke - 12.01.2022

2021

Expert Interview Prof. M. Brainin - 22.12.2021Webinar Report - Innovative strategies to advance severe TBI treatment - 01.12.2021Best Drug for Stroke Recovery - 17.11.2021Webinar: The renaissance of neuroprotection in times of recanalization therapies - 03.11.2021Watch – How Cerebrolysin® works after stroke - 28.09.2021Free Webinar in October - 17.09.2021Reducing Complications related to Thromolysis and Thrombectomy - 07.09.2021The relevance of neurorehabilitation in acute and chronic stroke - 18.08.2021New hope for TBI patients - 04.08.2021Cerebrolysin® included in EAN Guideline! - 21.07.2021Acute and longterm neurorecovery after TBI - 05.07.2021Cerebrolysin® improves Blood-Brain-Barrier (BBB) Integrity - 21.06.2021New Webinar: The relevance of neurorehabilitation in acute and chronic stroke - 02.06.2021New International Guidelines in Stroke and in subacute Rehabilitation - 12.05.2021New Webinar: Acute and longterm neurorecovery after TBI - 28.04.2021New Meta-Analysis confirms Efficacy of Cerebrolysin® - 08.03.2021Webinar: New international Guidelines in stroke and subacute rehabilitation - 26.02.2021New Treatment for severe TBI Patients - 12.02.2021The International Cerecap-Research Project - 28.01.2021

2020

New Treatment Concepts in Stroke - 09.12.2020Why Cerebrolysin® might help in COVID-19 - 26.11.2020Canadian Stroke Rehabilitation Guidelines - 30.10.2020Cerebrolysin® included into German Neurorehab Guidelines - 24.09.2020The renaissance of neuroprotection in times of recanalization therapies - 09.07.2020Outcomes - Remarkable Cases in Neurorecovery - 03.06.2020Disorders of consciousness after stroke - 29.04.2020CAPTAIN Trial - Positive Results in TBI - 28.02.2020Award for AUREUS - 30.01.2020New Hope for Chronic Stroke Patients - 10.01.2020

2019

Advances in the treatment of TBI and stroke - 24.10.2019Innovative treatment option for TBI - 27.09.2019Neuro-Rehabilitation has a big potential! - 16.09.2019Welcome to the 26th IMMM - 20.08.2019Report of ESOC symposium 2019 available! - 09.07.2019New TBI data presented at EAN 2019, Oslo - 05.06.2019ESOC 2019: Invitation to EVER satellite symposium - 25.04.2019Effective pharmacological drug for recovery after stroke available! - 21.02.2019EVER's initiative on medical education - 14.01.2019

2018

New Austrian Rehabilitation Guideline Available - 10.12.2018Highlights of the 25th IMMM - 06.11.2018New meta-analysis about safety and efficacy of Cerebrolysin® - 08.10.2018Scientific report of the satellite symposium during EAN 2018 - 18.09.2018The IMMM celebrates its 25th anniversary - 09.08.2018Scientific symposium review of the ESOC 2018 - 02.07.2018EAN Congress, Lisbon - 05.06.2018ESOC 2018: Invitation to stroke recovery symposium - May 17th - 02.05.2018Transcranial Direct Current Stimulation (tDCS) - 11.04.2018World Stroke Day Congress in Moscow 2017 - 19.03.2018Video presentation about CARS study - 01.02.2018

2017

Neurorecovery in actue stroke treatment & Complications and rehabilitation after stroke - 18.12.2017New holistic approach in Stroke treatment - 06.10.2017Review of the 3rd Congress of the European Academy of Neurology 2017 - 11.08.2017Review of the 3rd European Stroke Organisation Conference 2017 - 06.07.2017Don't miss the EAN symposium on Stroke Recovery - 24.05.2017Voucher for free Rehabilitation set - 24.05.2017AD/PD 2017 Summary - 19.04.2017ESOC 2017: Invitation to Stroke Recovery Symposium - May 18th - 12.04.2017Announcement AD/PD 2017 - 07.03.2017Improving Life After Stroke - The Post Stroke Checklist - 10.02.2017

2016

Review of the 23rd International Mondsee Medical Meeting - 06.12.2016Advances in Sub-Acute Stroke Motor Recovery - 11.10.2016CARS trial - rehabilitation after stroke with Cerebrolysin® - 22.07.2016Review 2nd European Stroke Organisation Conference 2016 - 23.06.2016

Notice to U.S. Visitors

Please be advised that Cerebrolysin is not registered with the U.S. Food and Drug Administration (FDA) and is not approved for sale or distribution in the United States.

Cerebrolysin is a prescription medication for use under the supervision of an authorized health care professional. For any medical inquiries, please consult with a healthcare professional.